Pfizer and Valeant both posted brand valuation increases greater than 30% in this year's Brand Finance ranking.
Pfizer's biosimilar of blockbuster Remicade looks to be headed to the U.S. market this year after getting very favorable treatment from an FDA advisory committee. Most importantly, Inflectra was recommended for all indications, a key to the drug maxing out its sales potential, as it goes head-to-head with Johnson & Johnson's Remicade, a drug that brought in more than $6.5 billion in the U.S. last year.
Pfizer's planned $160 billion merger with Allergan has some researchers worried the company will embrace its counterpart's austere approach to R&D and mount major layoffs.
Newsmaker pharmas Pfizer and Valeant Pharmaceuticals both saw brand valuation increases of more than 30% in this year's Brand Finance ranking.
A group of independent FDA advisers voted in favor of OK'ing Pfizer and Celltrion's take on the blockbuster inflammation treatment Remicade for all of the reference drug's approved indications, unswayed by protests from Johnson & Johnson.
Pfizer's Ibrance has already been prescribed to more than 20,000 patients, and the company says it has a "very heavy" clinical trial program testing it in multiple types of breast cancer and beyond.
Pfizer is shaking up its corporate structure again as it prepares to merge with Allergan and further lays the groundwork for a potential split in a few years. The structural rejig pushes out Geno Germano, who has been leading Pfizer's global innovative pharma business, and elevates one top Allergan manager, Bill Meury, to the combined company's commercial leadership team.
Pfizer's Ibrance has been steamrolling since it nabbed an early FDA go-ahead last February. And even with competition coming up the pipeline from the company's Big Pharma rivals, Pfizer intends to keep it that way.
FDA staff signaled support for Celltrion's biosimilar of Johnson & Johnson's Remicade in documents released ahead of a key panel vote, a positive development for the South Korean company as it works with Pfizer to tap the U.S. market.
Cambridge, MA-based Affinivax launched in November 2014 with a $4 million Gates Foundation investment and plans to develop a pneumococcal vaccine that it believes could go beyond Prevnar, the best-selling vaccine in the world. Now, the biotech is announcing $2.5 million in follow-on funding from the Gates Foundation, which it will use to advance its lead candidate, CEO Steve Brugger told FierceVaccines.